Is trimethoprim‑sulfamethoxazole (Bactrim) effective for treating Moraxella infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Bactrim Treat Moraxella?

Yes, Bactrim (trimethoprim-sulfamethoxazole) has in vitro activity against Moraxella catarrhalis, but clinically significant resistance rates of up to 50% have been reported, making it a suboptimal choice for empiric therapy.

Key Clinical Considerations

Susceptibility Profile

While Moraxella catarrhalis is technically susceptible to trimethoprim-sulfamethoxazole in laboratory testing, the guideline evidence reveals a critical caveat: TMP-SMX resistance rates as high as 50% have been occasionally reported 1. This high resistance rate substantially undermines its reliability as a treatment option.

The 2011 European guidelines specifically note that despite nearly universal β-lactamase production in M. catarrhalis (making it resistant to amoxicillin and ampicillin), resistance to other antibacterial agents has developed, with TMP-SMX being particularly problematic 1.

FDA-Approved Indications

The FDA label for Bactrim does not list Moraxella catarrhalis among its approved indications 2. The approved respiratory indications include:

  • Acute otitis media due to Streptococcus pneumoniae or Haemophilus influenzae
  • Acute exacerbations of chronic bronchitis due to S. pneumoniae or H. influenzae

The absence of M. catarrhalis from this list is telling.

Research Evidence Confirms High Resistance

Multiple studies demonstrate problematic resistance patterns:

  • A 2002 study found that M. catarrhalis was "highly resistant against Trimethoprim Sulfamethoxazole" 3
  • A 2008 Finnish surveillance study monitoring 14,138 M. catarrhalis isolates found no statistically significant connection between TMP-SMX use and resistance, suggesting resistance is already widespread and endemic rather than usage-dependent 4

Preferred Alternatives

For M. catarrhalis infections, use β-lactam/β-lactamase inhibitor combinations (amoxicillin-clavulanate) or other enzyme-stable β-lactams, macrolides, or tetracyclines 1. These agents maintain excellent activity:

  • Amoxicillin-clavulanate: All isolates remain susceptible
  • Macrolides: Very active
  • Tetracyclines: Very active

Clinical Bottom Line

While Bactrim may work against some M. catarrhalis strains in vitro, the combination of:

  1. High and unpredictable resistance rates (up to 50%)
  2. Lack of FDA approval for this indication
  3. Availability of superior alternatives with reliable activity

makes Bactrim an inappropriate choice for treating Moraxella catarrhalis infections in clinical practice. Choose amoxicillin-clavulanate or a macrolide instead.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.